AI breast cancer screening: DBT scores, 2D mammography risk assessment, startup grants
In digital breast tomosynthesis screening, the AI score for true positive exams is more than double that of true negatives. Medara received a $400,000 NCI grant and MammoCheck a €500,000 grant for AI breast cancer risk assessment and FDA/CE approval.
Who is affected and how
- doctor
- Radiologists need to learn the clinical interpretation of AI scores in screening and the new options for risk-based screening.
- medtech company
- Early-stage companies are using grant funding to move toward regulatory approval.
Sources
- Can AI Bolster Breast Cancer Detection in DBT Screening? | Diagnostic Imagingdiagnosticimaging.com · Aug 4, 2026
- AI Cancer Detection: What a Strong Study Must Showcancerexplained.org · Aug 6, 2026
- AI-Driven Risk Assessment is Transforming Breast Cancer Screening | CancerNetworkcancernetwork.com · Aug 8, 2026
- AdventHealth expands AI-driven cancer risk assessment to system-wide screening and personalised care | Noah Intelligencenoah-news.com · Aug 8, 2026
- Medara nets $400,000 NCI grant for AI breast cancer risk platformauntminnie · Aug 4, 2026
- medara nets $400,000 NCI grant for AI breast cancer risk platform | AuntMinnieauntminnie.com · Aug 4, 2026
- MammoCheck lands €500K grant to chase FDA and CE approval for AI breast screeningdealroom · Aug 4, 2026
- MammoCheck lands €500K grant to chase FDA and CE approval for AI breast screening | Dealroom Newsdealroom.co · Aug 4, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.